Kera Capital Partners Inc. Invests $258,000 in Cencora, Inc. (NYSE:COR)

Kera Capital Partners Inc. acquired a new position in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,148 shares of the company’s stock, valued at approximately $258,000.

Several other large investors also recently added to or reduced their stakes in the business. Concord Wealth Partners purchased a new stake in shares of Cencora in the 3rd quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC raised its stake in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Cencora during the third quarter valued at approximately $41,000. Fairscale Capital LLC bought a new stake in Cencora during the second quarter valued at approximately $54,000. Finally, Modus Advisors LLC purchased a new position in Cencora in the 4th quarter worth approximately $54,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock valued at $22,862,734 in the last quarter. Company insiders own 15.80% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of several research reports. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company decreased their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Finally, Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Cencora Stock Performance

Shares of COR stock opened at $242.11 on Friday. The company has a market capitalization of $46.80 billion, a P/E ratio of 32.24, a PEG ratio of 1.48 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The stock has a 50 day moving average price of $237.52 and a two-hundred day moving average price of $233.93.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a dividend of $0.55 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.